This page is for clinic owners and marketing teams producing website content, social media posts, or paid ads targeting UK patients. It tells you what phrases get clinics reported, what the ASA and CMA can now do about it, and where the lines moved in 2025.
UK healthcare advertising does not have a single statute. It runs through four overlapping systems: the CAP Code (advertising self-regulation), medicines law enforced by the MHRA, consumer protection law now enforced directly by the CMA, and professional codes enforced by the GMC, GDC and NMC. A campaign can pass one layer and breach another — which is how clinics get caught without realising it. The practical shift since April 2025 is that advertising non-compliance now carries direct financial penalties, not just reputational damage through published ASA rulings.
The three patterns that catch clinics most often are prescription medicine references in public-facing ads (naming Botox or weight-loss injections counts), outcome language that reads as a guarantee rather than a typical result, and urgency tactics applied to cosmetic or invasive procedures. The ASA’s 2025 liquid-BBL rulings confirmed that Black Friday framing for surgery bookings is enough to get an ad pulled — even if the discount itself is accurate. This page covers all three in plain English, with rewrites.
The UK Trigger Word List
These are the phrases most consistently flagged in UK compliance reviews — the ones ASA and MHRA have specifically acted on. Change them first before anything else.
| What you wrote | Why it’s a problem | What to write instead |
|---|---|---|
| Book your Botox now | Botox is a prescription-only medicine (POM). Advertising it publicly — including just naming it — breaches the Human Medicines Regulations 2012 and CAP Rule 12.12. MHRA enforced this in 2025 against multiple providers. | Book a consultation for anti-wrinkle treatment |
| Weight-loss injections from £X / GLP-1 available | GLP-1 receptor agonists are POMs. Public advertising — including “from £X” pricing — is prohibited. MHRA required multiple clinics and comparison sites to remove this language in 2025. | Medically supervised weight management programme — from £X per month |
| Guaranteed results | CAP Rules 3.7 and 12.9 prohibit suggestions that a treatment is guaranteed to work. GMC guidance also prohibits false guarantees of clinical outcomes. No evidence base can support this. | Most patients report [X outcome] — results vary by individual |
| Safe and risk-free / completely risk-free | CAP Rule 12.9 explicitly bans suggestions that a product or therapy is “absolutely safe” or “without side-effects.” ASA has upheld complaints against clinics using this in cosmetic contexts. | Our safety protocols include [specific measure] — all risks are discussed at consultation |
| No downtime / zero recovery | Outcome guarantee. CAP’s cosmetic guidance treats “no downtime” as an objective claim requiring evidence — and most procedures do involve some recovery variation. Risks must not be trivialised. | Minimal recovery time for most patients — your clinician will advise based on your treatment |
| 100% success rate / 99% success | Unverifiable superlative statistic (CAP Rule 3.7). Individual clinical outcomes cannot be aggregated into a guarantee. Even if you hold data, the claim implies universality you cannot prove. | High patient satisfaction across [X] procedures — [source] (with peer-reviewed citation) |
| Best clinic in London / best surgeon in the UK | Unverifiable superlative. CAP cosmetic guidance distinguishes service-level claims (“leading clinic”) from practitioner claims — “best” requires substantiation at the level consumers understand, which is unachievable. | Specialist [specialty] clinic — GMC registered practitioners |
| Before and after [in any paid ad or social promotion] | CAP Rule 12.23 bans before/after imagery in cosmetic intervention advertising. Before/after for Botox specifically can constitute POM advertising. ASA treats these as objective claims requiring proof they’re genuine, representative and unmanipulated. | Remove from ads entirely — educational before/after content may be published on a clinical information platform, not in promotional posts |
| Black Friday — 3 slots left / book before midnight | Urgency and scarcity framing for cosmetic or invasive procedures. ASA’s 2025 liquid-BBL rulings held this trivialises risk and pressures consumers into ill-considered decisions. GMC’s professional guidance reaches the same conclusion. | We have availability this month — book a consultation to discuss your options |
| MHRA-approved / MHRA-registered and endorsed | MHRA’s public registration database explicitly states registration is not accreditation, certification, approval or endorsement. Using MHRA logos or endorsement language is prohibited. | Our devices carry CE/UKCA marking — [device name] is registered with the MHRA |
5 Real-World Rewrites — Before & After
These are the kind of captions UK clinic marketing teams write every week. Each one has a specific problem, and a version that passes.
Problems: “pain-free” = outcome guarantee; “100% success rate” = unverifiable statistic (CAP 3.7); “guaranteed” = absolute outcome claim (CAP 12.9); “limited slots / don’t miss out” = urgency pressure on a significant dental procedure (CAP cosmetic guidance); no GDC registration number.
Why it works: No outcome guarantees. GDC registration signals compliance. Recovery language is qualified. No urgency framing. Directs to consultation, which is where clinical advice begins.
Problems: “safest” = unsubstantiated safety claim (CAP 12.9); “zero downtime” = false outcome claim; “guaranteed” = prohibited (CAP 12.9 + GMC guidance); “spaces filling fast” = pressure tactic for invasive surgery (ASA 2025 rulings); “summer body” framing exploits body insecurity (CAP cosmetic guidance).
Why it works: Transparent pricing with a suitability caveat. Honest recovery timeline. GMC registration referenced. No urgency, no body-insecurity framing, no outcome guarantee.
Problems: “Botox” in a public promotional post = POM advertising (Human Medicines Regulations 2012 + CAP 12.12) — this alone is a criminal offence under MHRA; before/after reference = CAP Rule 12.23 violation; “no side effects for 98%” = unverifiable statistic requiring a specific peer-reviewed source.
Why it works: No POM named. Treatment positioned as prescription-led — which it legally is. No before/after. No statistics without sources. No pricing in the ad itself (safe harbour).
Problems: “forever” = absolute outcome claim; “completely pain-free” + “zero downtime” = outcome guarantees (CAP 12.9); “94% full clearance after one session” = statistical claim requiring peer-reviewed citation with identical protocol; “January offer ends Sunday” = urgency pressure for a clinical procedure; “revolutionary” = banned vocabulary in MSF style guidelines.
Why it works: Improvement framed as typical, not guaranteed. Recovery honest and qualified. No urgency. Clinician credential cited. No unverified statistics.
Problems: No #ad disclosure = CAP misleading advertising + ASA influencer rules (commercial arrangement must be “obviously identifiable”); “Botox” named = POM advertising to the public — both influencer and clinic are exposed; “zero swelling, totally pain-free” = outcome guarantee; discount code = incentivised content requiring disclosure; health professional endorsement of POM via third party = additional MHRA exposure.
Why it works: #Ad visible at the start of the post (ASA requirement — not buried). No POM named. No outcome claim. No discount code. Directs to consultation, not treatment. GMC registration mentioned.
What Is Absolutely Prohibited — No Exceptions
These are not grey areas — each reflects an explicit statutory prohibition, a confirmed ASA enforcement position, or a criminal offence under MHRA.
The rule: Prescription-only medicines may not be advertised to the public. Naming a POM in a public-facing promotional context — website, social post, influencer content — is prohibited regardless of how it’s framed.
In practice: “Book your Botox,” “weight-loss injections available,” “Ozempic / Wegovy for weight loss,” “GLP-1 programme from £X,” any reference to specific anti-wrinkle injection brand names in public ads. MHRA enforced this against botulinum toxin providers in 2025 and against weight-loss medicine advertisers across multiple platforms.
The rule: Before and after images for cosmetic interventions are banned in advertising contexts. For Botox specifically, before/after photos are additionally likely to constitute POM advertising. Marketers must hold evidence that images are genuine, dated, unmanipulated and representative — and even then, they cannot be used in ads.
In practice: Instagram carousels showing rhinoplasty results, Facebook ads with lip-filler comparisons, any promotional social post including clinical before/after photography. Educational use on a clinical information platform (not in ads) is the only permitted context.
The rule: No suggestion that a treatment is guaranteed to work, absolutely safe, or without side-effects. This applies across all media. GMC guidance for doctors adds a professional-ethics layer: no false guarantees of clinical outcomes, no claiming interventions are risk-free.
In practice: “Guaranteed results,” “100% success rate,” “pain-free guaranteed,” “zero risk,” “no side effects,” “permanent solution,” “scar-free,” “no downtime.” Each triggers an independent breach.
The rule: Time pressure, scarcity cues and promotional urgency tactics applied to cosmetic or invasive treatments are irresponsible and breach CAP. The ASA’s 2025 liquid-BBL rulings are black-letter precedent: “limited spaces,” countdown timers, “Black Friday surgery deals” and “don’t miss out” language for serious procedures was upheld as trivialising risk.
In practice: “Only 2 slots left for abdominoplasty,” “Black Friday filler offer — today only,” “book before midnight to lock in this price,” countdown timers in ads for any invasive procedure.
The rule: From December 2025, CAP’s code explicitly prohibits fake consumer reviews, requires disclosure where reviews were incentivised, and bans publishing review information in a misleading way — including selective publication of positives or suppression of negatives. The CMA’s April 2025 guidance makes this simultaneously a consumer-law enforcement issue with financial penalties up to 10% of global turnover.
In practice: Buying Google reviews, posting fabricated patient testimonials, running “leave us a 5-star review and get 10% off your next treatment” without labelling all resulting reviews as incentivised, systematically removing negative reviews.
The rule: Since 25 May 2022, ads for cosmetic procedures must not be targeted at, or placed in media likely to be seen predominantly by, under-18s. This applies across all channels including social media.
In practice: Running cosmetic clinic ads on TikTok without age-restriction settings, using influencers whose audience is primarily under-18, placing cosmetic ads adjacent to content known to appeal to minors.
The rule: MHRA’s public registration database explicitly states registration is not accreditation, certification, approval or endorsement. Using MHRA logos or making such endorsement claims is prohibited.
In practice: “MHRA-approved clinic,” “MHRA-certified treatment,” “approved by the UK medicines regulator,” MHRA logo placed near product or treatment descriptions.
The rule: Where a clinic has paid, gifted treatment, offered a discount, given affiliate commission or otherwise induced content, that post is an ad and must be obviously identifiable as such from the start. The ASA’s LIFT Aesthetics ruling combined both POM promotion and undisclosed commercial intent — both layers were independently enforced.
In practice: Any influencer post mentioning clinic treatments, pricing or booking where there is any commercial arrangement — without #Ad or equivalent placed prominently at the top of the post.
The Grey Areas — Allowed Under Specific Conditions
Not outright banned — but the specific conditions below determine whether you’re compliant or exposed.
Allowed if: The statistic comes from a peer-reviewed study matching your exact treatment protocol; it’s cited in the ad or footnoted on the landing page; it describes a population outcome (not an individual guarantee); it’s presented accurately without cherry-picking.
Crosses the line if: The study used a different patient population, procedure, or setting; the statistic is extrapolated to imply guaranteed individual outcomes; no source is visible to consumers.
Allowed if: Published on a professional clinical information platform — not in any paid ad or promotional social post; images are genuine, dated, signed by the patient, unmanipulated, and representative of typical results; raw files and editing records are retained.
Crosses the line if: Used in any paid promotion, boosted social post, or promotional story; images are digitally enhanced in the treated area; presented without representative context.
Allowed if: Clearly labelled as an individual patient experience; genuine and verifiable; representative of typical results; does not imply the same outcome is available to all patients; not incentivised, or if incentivised, clearly disclosed.
Crosses the line if: Implies universal results (“this will work for you too”); involves celebrities whose profile exaggerates the likelihood of particular outcomes; omits any mention of risk; testimonial was obtained in exchange for free or discounted treatment without disclosure.
Allowed if: Quoted price is the total inclusive price including all unavoidable charges; any conditional element (consultation fee, consumables, follow-up) is clearly stated; no misleading comparison to a higher previous price unless the higher price was genuinely charged for a meaningful period.
Crosses the line if: “From £X” conceals a mandatory consultation fee that all patients pay; “was £2,000, now £800” uses a reference price that was never genuinely the standard price; unavoidable travel or accommodation for procedures abroad is excluded from the headline price.
Allowed if: GMC/GDC/NMC registration number is included; specialist title matches the regulatory designation exactly; “doctor-led” or “consultant-led” claims are supported at the clinic level, not just by one individual.
Crosses the line if: “Specialist” or “consultant” is used without the regulated professional designation; credential claims cannot be verified against the relevant register; “UK’s leading surgeon” or similar superlatives are used without substantiation.
Allowed if: The discount is mathematically accurate; the promotion does not apply pressure tactics to a cosmetic or invasive treatment decision; the offer period is genuine.
Crosses the line if: The discount is combined with urgency language for surgery, fillers, or any invasive procedure (“last chance,” “today only,” “limited spaces”); the reference price was not genuinely charged before the discount.
Allowed if: Current CQC rating is displayed on the website and at premises for rated services. GDC-registered practices must also state whether they are NHS, mixed or private.
Crosses the line if: CQC rating is absent from the website; an outdated rating is displayed; a practice inherits regulatory history from a different operator but displays the previous operator’s rating.
The Cross-Border Trap for CEE Clinics
⚠ If your clinic is outside the UK and targeting UK patients — read this
Post-Brexit, the UK operates its own advertising standards entirely independently from the EU. The CAP Code applies to any advertising targeting UK consumers regardless of where the advertiser is based. UK targeting is inferred from sterling pricing, “.uk” domains, UK contact details, or geotargeted social ads pointed at UK users. A Hungarian, Polish or Romanian clinic running English-language Instagram ads at UK audiences is subject to CAP — and to MHRA criminal enforcement if those ads name prescription medicines.
CAP issued a specific enforcement notice in February 2024 to cosmetic surgery providers based abroad. Its March 2026 enforcement report documented more than 4,000 paid ads monitored across two phases, with common breaches from non-UK advertisers including “mommy makeover” messaging, body-insecurity exploitation, and time-limited offers. CAP’s report confirmed materially improved compliance after enforcement action — which confirms that foreign clinics should not assume UK reach without UK accountability.
The Legal Framework — For Reference
For those who want the statutory detail and enforcement architecture behind the practical rules above.
| Law / Code | What it covers | Enforcing authority | Max penalty |
|---|---|---|---|
| CAP Code, Section 12 (especially Rules 12.9, 12.12, 12.23) | All non-broadcast advertising — websites, social media, paid digital, outdoor; medicines claims, cosmetic interventions, before/after restrictions, POM prohibition | ASA / CAP | No direct fine; mandatory removal + public ruling + CMA/Trading Standards referral |
| BCAP Code, Section 11 | Broadcast advertising — TV, radio; health claims require central clearance | ASA / Ofcom | Ofcom licensing sanction for broadcasters; ASA referral |
| Human Medicines Regulations 2012 | Prohibition on advertising POMs to the public; unlicensed medicine promotion | MHRA | Up to 2 years imprisonment + unlimited fine (criminal) |
| Digital Markets, Competition and Consumers Act 2024 (DMCCA), Part 4, Chapter 1 | Unfair commercial practices, misleading actions/omissions, fake reviews, aggressive practices — live 6 April 2025 | CMA / Trading Standards | Up to 10% global turnover or £300,000 (greater); binding directions |
| GMC Good Medical Practice + Cosmetic Interventions Guidance (updated December 2024) | Professional advertising obligations for registered doctors — factual, non-exploitative, no risk-free or outcome-guarantee claims, no urgency tactics | GMC / MPTS | Warning, conditions, suspension, erasure from medical register |
| GDC Advertising Guidance | Dental advertising obligations — accuracy, GDC number required, NHS/private disclosure, specialist title control, no misleading claims | GDC | Reprimand, conditions, suspension, erasure |
| CQC Regulation 20A | Rated services must display current CQC rating on website and at premises | CQC | Regulatory enforcement; marketing risk if ratings information is false or misleading |
| NHS Identity Rules (England) | NHS-funded services must be clearly branded NHS; provider identity transparent; NHS logo restricted to NHS-funded content | NHS England / CQC | NHS Identity breach; regulatory referral |
Enforcement cases and precedents
In 2025, MHRA required multiple clinics, online pharmacies and comparison-style sites to remove advertising that referenced weight-loss injections, GLP-1 receptor agonists or specific brand names in public-facing pages. The enforcement confirmed that “from £X” pricing for POM treatments is itself prohibited — not just named-brand references. A separate 2025 MHRA investigation upheld a complaint about promotion of unlicensed botulinum toxin at a UK industry conference, confirming the POM-advertising prohibition extends to professional and B2B contexts.
ASA’s 2025 liquid-BBL rulings represent the most significant cosmetic-advertising precedent of the year. Multiple aesthetic clinics had their ads ruled against for combining Black Friday urgency language, scarcity messaging and body-insecurity framing with invasive procedure advertising. The ASA held each element independently irresponsible — urgency alone was enough for an upheld ruling regardless of the accuracy of the underlying offer. CAP’s March 2026 cosmetic-surgery-abroad enforcement report documented 4,000+ monitored ads, materially improved compliance rates after intervention, and confirmed that foreign providers targeting UK consumers are within ASA jurisdiction.
Legal disclaimer: This page provides general information about United Kingdom medical advertising regulations for educational purposes only and does not constitute legal advice. Regulations change — the DMCCA came into force April 2025, CAP fake-review rules changed December 2025, and FCA BNPL regulation is scheduled July 2026. Verify all compliance requirements with a qualified legal professional before publishing any marketing materials. MedicalServiceFinder.com accepts no liability for decisions made based on this content.
Last updated: June 2026 | Primary sources: CAP Code (asa.org.uk) · Human Medicines Regulations 2012 · DMCCA 2024 · GMC Cosmetic Interventions Guidance · GDC Advertising Guidance · MHRA advertising guidance
